Hall Capital Management Co. Inc. Takes $461,000 Position in The Clorox Company (NYSE:CLX)

Hall Capital Management Co. Inc. bought a new position in The Clorox Company (NYSE:CLX - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 2,836 shares of the company's stock, valued at approximately $461,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Vanguard Group Inc. raised its stake in Clorox by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 15,507,152 shares of the company's stock valued at $2,518,517,000 after purchasing an additional 124,428 shares in the last quarter. Geode Capital Management LLC lifted its position in Clorox by 2.3% in the fourth quarter. Geode Capital Management LLC now owns 3,098,302 shares of the company's stock valued at $501,925,000 after purchasing an additional 69,969 shares during the last quarter. Stifel Financial Corp boosted its position in Clorox by 0.4% during the 4th quarter. Stifel Financial Corp now owns 2,344,408 shares of the company's stock valued at $380,761,000 after buying an additional 9,582 shares during the period. Norges Bank bought a new stake in shares of Clorox in the fourth quarter worth about $259,041,000. Finally, Northern Trust Corp increased its stake in shares of Clorox by 18.2% during the fourth quarter. Northern Trust Corp now owns 1,494,265 shares of the company's stock valued at $242,684,000 after buying an additional 230,173 shares during the period. Hedge funds and other institutional investors own 78.53% of the company's stock.

Insider Transactions at Clorox

In other news, Director Pierre R. Breber acquired 4,000 shares of Clorox stock in a transaction that occurred on Wednesday, May 7th. The stock was purchased at an average price of $136.57 per share, for a total transaction of $546,280.00. Following the purchase, the director now directly owns 4,000 shares in the company, valued at $546,280. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 0.57% of the company's stock.

Clorox Stock Performance

Shares of NYSE CLX traded up $0.73 during trading on Friday, hitting $131.72. The company had a trading volume of 564,916 shares, compared to its average volume of 1,334,977. The company has a debt-to-equity ratio of 20.52, a quick ratio of 0.60 and a current ratio of 0.94. The Clorox Company has a 12 month low of $127.77 and a 12 month high of $171.37. The firm has a market capitalization of $16.24 billion, a P/E ratio of 35.99, a price-to-earnings-growth ratio of 2.62 and a beta of 0.60. The stock has a 50 day simple moving average of $138.50 and a 200 day simple moving average of $151.47.

Clorox (NYSE:CLX - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported $1.45 earnings per share for the quarter, missing analysts' consensus estimates of $1.57 by ($0.12). The business had revenue of $1.67 billion during the quarter, compared to the consensus estimate of $1.74 billion. Clorox had a return on equity of 316.87% and a net margin of 6.38%. The business's revenue was down 8.0% on a year-over-year basis. During the same period last year, the company earned $1.71 EPS. As a group, analysts anticipate that The Clorox Company will post 7.15 earnings per share for the current year.

Wall Street Analyst Weigh In

CLX has been the topic of several research reports. Wells Fargo & Company cut their price objective on Clorox from $145.00 to $142.00 and set an "equal weight" rating on the stock in a research report on Tuesday, May 6th. JPMorgan Chase & Co. cut their price target on shares of Clorox from $151.00 to $144.00 and set a "neutral" rating on the stock in a report on Tuesday, May 6th. Morgan Stanley lowered their price objective on Clorox from $165.00 to $150.00 and set an "equal weight" rating on the stock in a research report on Tuesday, May 6th. Royal Bank of Canada reissued a "sector perform" rating and issued a $150.00 target price on shares of Clorox in a report on Thursday, January 30th. Finally, Evercore ISI set a $140.00 price objective on Clorox and gave the stock an "underperform" rating in a report on Tuesday, May 6th. Three analysts have rated the stock with a sell rating, eleven have given a hold rating and one has assigned a buy rating to the stock. According to MarketBeat.com, Clorox has a consensus rating of "Hold" and an average price target of $151.23.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.